Drug intelligence / Profile preview

telmisartan + s-amlodipine + atorvastatin

Development stage
Unknown
Lead developer
Chong Kun Dang Pharmaceutical
Modality
Small Molecules
Administration
Oral
01

Overview

Telmisartan + s-amlodipine + atorvastatin is a fixed-dose combination drug used primarily for the management of patients with both hypertension and dyslipidemia. Telmisartan is an angiotensin II receptor blocker (ARB) that lowers blood pressure by blocking the action of angiotensin II, leading to vasodilation. S-amlodipine is the S-enantiomer of amlodipine, a calcium channel blocker (CCB), which relaxes vascular smooth muscle and further reduces blood pressure. Atorvastatin is a statin that inhibits HMG-CoA reductase, reducing cholesterol synthesis in the liver and lowering LDL cholesterol levels while modestly increasing HDL cholesterol. This triple combination targets cardiovascular risk factors by simultaneously controlling high blood pressure and abnormal lipid profiles[6][3]. It is indicated for patients who require all three agents to achieve optimal control.

Brand names
Tesarto-APleotor TArbitel-AVTeleact StTelsartan AtrTemsan CVLipisarStalia ACreslip
Other names
telmisartan/atorvastatin/s-amlodipine
02

Targets

CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)AGTR1 (Angiotensin II Type-1 receptor)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)

Beyond the preview

Go deeper on telmisartan + s-amlodipine + atorvastatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on telmisartan + s-amlodipine + atorvastatin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call